This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Akero Therapeutics (AKRO) Up on Positive Data from NASH Study
by Zacks Equity Research
Akero Therapeutics (AKRO) reports positive top-line data from a mid-stage study evaluating its lead candidate, efruxifermin (EFX), in patients with NASH, fibrosis stage 2 or 3 (F2-F3). Stock up.
Why Is Axsome (AXSM) Up 26.9% Since Last Earnings Report?
by Zacks Equity Research
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Intercept (ICPT) Up 15.4% Since Last Earnings Report?
by Zacks Equity Research
Intercept (ICPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Implied Volatility Surging for Intercept Pharmaceuticals (ICPT) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Intercept Pharmaceuticals (ICPT) stock based on the movements in the options market lately.
Intercept (ICPT) Settles Litigation With Dr. Reddy's for Ocaliva
by Zacks Equity Research
Intercept (ICPT) enters into a settlement agreement with Dr. Reddy's for lead drug Ocaliva's generic version.
Intercept (ICPT) Earnings Miss, Sales Top Estimates in Q2 (Revised)
by Zacks Equity Research
Intercept (ICPT) posts a wider Q2 loss while sales beat estimates. The company reissues guidance.
Intercept Pharmaceuticals (ICPT) Reports Q2 Loss, Beats Revenue Estimates (Revised)
by Zacks Equity Research
Intercept (ICPT) delivered earnings and revenue surprises of -28.30% and +5.86%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Intercept (ICPT) Earnings and Sales Miss Estimates in Q2
by Zacks Equity Research
Intercept (ICPT) posts a wider Q2 loss and sales miss estimates. The company reissues guidance.
Intercept Pharmaceuticals (ICPT) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Intercept (ICPT) delivered earnings and revenue surprises of -28.30% and 24.34%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Pliant Therapeutics, Inc. (PLRX) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Pliant Therapeutics, Inc. (PLRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Roundup: ICPT's Study Data, NVAX Vaccine Gets EUA, VERU Up on Data
by Zacks Equity Research
Regulatory and other updates from Intercept (ICPT) and VERU are a few key highlights from the biotech sector during the past week.
Intercept (ICPT) Reports Positive Data From NASH Study on OCA
by Zacks Equity Research
Intercept (ICPT) reports positive top-line results from a new analysis of its ongoing pivotal phase III REGENERATE study of OCA in patients with liver fibrosis due to NASH.
Intercept (ICPT) Ocaliva Drives Growth, Pipeline Setbacks Hurt
by Zacks Equity Research
Intercept (ICPT) currently has only one marketed product in its portfolio, Ocaliva, for treating PBC. The company continues to evaluate the potential of OCA in treating progressive liver diseases.
Intercept (ICPT) Announces Delay in Meeting With the FDA
by Zacks Equity Research
Intercept (ICPT) faces yet another setback as its resubmission for NDA for OCA for NASH gets delayed.
Pfizer (PFE) Gets Fast Track Designation for NASH Therapy
by Zacks Equity Research
Pfizer (PFE) obtains Fast Track designation for its investigational combination therapy - ervogastat and clesacostat for the treatment of NASH.
The Zacks Analyst Blog Highlights Regeneron, Vertex, Intercept Pharmaceuticals, and Biohaven Pharmaceutical
by Zacks Equity Research
Regeneron, Vertex, Intercept Pharmaceuticals, and Biohaven Pharmaceutical are part of Zacks top Analyst Blog
Biotech Stock Roundup: REGN, VRTX Earnings Update, BHVN Up on Regulatory News
by Ekta Bagri
Earnings and regulatory updates from Regeneron (REGN) and Vertex (VRTX) are a few key highlights from the biotech sector during the past week.
Intercept (ICPT) Q1 Earnings Top, Ocaliva Sales Miss Estimates
by Zacks Equity Research
Intercept (ICPT) posts a narrower-than-expected loss in the first quarter. Sales lag estimates.
Intercept Pharmaceuticals (ICPT) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Intercept (ICPT) delivered earnings and revenue surprises of 34.83% and 2.51%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Provention Bio, Inc. (PRVB) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Provention Bio, Inc. (PRVB) delivered earnings and revenue surprises of 22.22% and 20.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Acadia Pharmaceuticals (ACAD) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Acadia (ACAD) delivered earnings and revenue surprises of -42.86% and 6.68%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Bristol Myers Squibb (BMY) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Bristol Myers (BMY) delivered earnings and revenue surprises of 2.08% and 3.48%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Intercept (ICPT) Outperforms Industry in 3 Months: What Lies Ahead?
by Zacks Equity Research
Intercept (ICPT) lead drug Ocaliva holds ground amid challenges. A positive readout from the NASH studies will be a good boost for the stock in the year ahead.
Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Nurix Therapeutics, Inc. (NRIX) delivered earnings and revenue surprises of -6.74% and 9.68%, respectively, for the quarter ended February 2022. Do the numbers hold clues to what lies ahead for the stock?
Denali Therapeutics Inc. (DNLI) Moves 7.5% Higher: Will This Strength Last?
by Zacks Equity Research
Denali Therapeutics Inc. (DNLI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.